Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for TransCode Therapeutics Inc. (RNAZ : NSDQ)

• Company Description    TransCode Therapeutics is an emerging RNA oncology company. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. The company's lead therapeutic candidate includes TTX-MC138. TransCode Therapeutics is based in BOSTON. Number of Employees: 7

• Price / Volume Information    Yesterday's Closing Price: $9.07 Daily Weekly Monthly 20 Day Moving Average: 11,600 shares Shares Outstanding: 0.92 (millions) Market Capitalization: $8.32 (millions) Beta: 1.52 52 Week High: $399.00 52 Week Low: $6.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.61% -5.65% 12 Week -20.27% -21.70% Year To Date -90.39% -91.71%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6 Liberty Square #2382 - Boston,MA 02109 USA ph: 857-837-3099 fax: - alan.freidman@transcodetherapeutics.com http://www.transcodetherapeutics.com

• General Corporate Information    Officers Thomas A. Fitzgerald - Interim Chief Executive Officer and Chief Financia Philippe P. Calais - Chairman Erik Manting - Director Magda Marquet - Director Magda Marquet - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 89357L501 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 04/21/26 Share - Related Items Shares Outstanding: 0.92 Most Recent Split Date: 5.00 (0.04:1) Beta: 1.52 Market Capitalization: $8.32 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 04/21/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.30 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 96.29% vs. Previous Quarter: -11.13% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - -440.64 06/30/25 - -378.30 03/31/25 - -578.88 ROA 09/30/25 - -205.50 06/30/25 - -186.01 03/31/25 - -222.61 Current Ratio 09/30/25 - 1.60 06/30/25 - 5.27 03/31/25 - 5.20 Quick Ratio 09/30/25 - 1.60 06/30/25 - 5.27 03/31/25 - 5.20 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - 1.71 06/30/25 - 7.37 03/31/25 - 12.35 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©